Thymogen vs Larazotide acetate
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: EW Dipeptide, Glu-Trp
Thymogen is the brand name for L-Glu-L-Trp (glutamyl-tryptophan, the dipeptide EW), an immune-modulating peptide isolated from the calf thymus extract Thymalin. It is the smallest active piece of that thymic complex and is studied for boosting T-cell activity and immune function. It has been used clinically in Russia since 1990 but has never been evaluated or approved by any Western regulator, and rigorous independent trials are lacking.
Also: Larazotide, AT-1001
Larazotide is an 8-amino-acid oral peptide (GGVLVQPG) designed to tighten the junctions between gut lining cells, aimed at celiac disease. For years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. The honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 Meters Biopharma filed for Chapter 7 liquidation in July 2023. It is not approved anywhere.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Thymogen | Larazotide acetate |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymogen is meant to mimic what thymus-derived peptides do to the immune system. In experiments it has been reported to push T-cell differentiation, improve T-cell recognition of peptide-MHC complexes, shift the balance of intracellular cyclic nucleotides, and ramp up neutrophil chemotaxis and phagocytosis. In plain terms, it is proposed to wake up parts of the immune defense, especially in states where immunity is run down. Like other Khavinson peptides, it has also been described as influencing gene expression at the level of DNA, though the immunomodulatory effects are the better-documented part of its story. The exact molecular trigger that starts these effects is not fully pinned down. | Larazotide is modeled on a fragment of Vibrio cholerae zonula occludens toxin, a region that overlaps with zonulin, the human protein that loosens tight junctions in the gut wall. The idea is that it blocks zonulin signaling and helps tight junctions reassemble, so gluten fragments have a harder time slipping between cells into the tissue underneath, where they trigger the immune reaction in celiac disease. It acts locally in the gut lumen and is not meant to be absorbed. That is a reasonable hypothesis with lab and animal support, but it is worth being clear: larazotide does not stop the immune response to gluten itself, and no human trial proved it protects the gut lining on biopsy. |
| Common Dosing | 10-20 mg daily 1-2x daily, before meals | 0.5 mg three times daily before meals (trial dose) Three times daily, before meals |
| Administration | Oral capsules, also available as nasal spray in some regions | Oral capsule taken before meals, alongside a gluten-free diet (not instead of it) |
| Typical Duration | 30-day courses with 2-3 month breaks | 12 weeks of treatment in the phase 2b trial |
| Best Time to Take | Morning, before meals | About 15 minutes before each main meal (trial protocol) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The most-cited international study is Anisimov and colleagues in Biogerontology (2000), where the dipeptide was given to rats and was associated with a longer maximum lifespan and markedly lower tumor incidence, including a roughly 3.4-fold drop in blood cancers versus controls. That is an animal study, not a human trial. A large body of supporting clinical and laboratory data exists, but it is overwhelmingly Russian-language, older, and produced by groups connected to the original developers, with little independent Western replication. There are no modern randomized controlled trials by outside labs confirming the immune or anti-aging claims to current evidence standards. So the fair summary is: decades of use and a real animal signal for immune and anti-tumor effects, but the high-quality, independently verified human evidence that Western medicine would want is simply not there. | The key human study is a phase 2b trial published in Gastroenterology in 2015 (Leffler and colleagues, NCT01396213). It randomized 342 adults with celiac disease who still had symptoms on a gluten-free diet to 0.5 mg, 1 mg, or 2 mg three times daily or placebo for 12 weeks. Only 0.5 mg met the primary endpoint (symptom score 2.59 vs 2.88), with 26% fewer symptomatic days. The 1 mg and 2 mg doses did nothing measurable, an odd inverse dose response the authors could not explain (peptide aggregation was one guess), and most secondary endpoints missed. Safety looked similar to placebo. The phase 3 CedLara trial (NCT03569007) then tested the same 0.5 mg dose, but in June 2022 an interim analysis showed the number of patients needed to separate drug from placebo was too large to continue, and the trial was terminated. 9 Meters later pointed larazotide at COVID-related conditions such as MIS-C, then filed Chapter 7 in July 2023. We found no active development after that. Bottom line: one positive-ish phase 2b, one stopped phase 3, no approval. |
Frequently Asked Questions: Thymogen vs Larazotide acetate
What is the difference between Thymogen and Larazotide acetate?
Thymogen is a immune peptide that thymogen is the brand name for l-glu-l-trp (glutamyl-tryptophan, the dipeptide ew), an immune-modulating peptide isolated from the calf thymus extract thymalin. it is the smallest active piece of that thymic complex and is studied for boosting t-cell activity and immune function. it has been used clinically in russia since 1990 but has never been evaluated or approved by any western regulator, and rigorous independent trials are lacking. Larazotide acetate is a immune peptide that larazotide is an 8-amino-acid oral peptide (ggvlvqpg) designed to tighten the junctions between gut lining cells, aimed at celiac disease. for years it was the furthest-along celiac drug in development and it gets talked about online as a 'leaky gut' or zonulin blocker. the honest story is short: one phase 2b trial found a modest symptom benefit at the lowest dose only, the phase 3 trial was stopped in 2022 when it could not show a clear effect, and the sponsor 9 meters biopharma filed for chapter 7 liquidation in july 2023. it is not approved anywhere. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Thymogen or Larazotide acetate?
Neither is universally "better" - the choice depends on your specific goals. Thymogen is typically used for immune purposes, while Larazotide acetate is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Thymogen and Larazotide acetate be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Thymogen and Larazotide acetate together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.